2026-2027
Committee, Task Force, and Work Group Appointments

NABP provides guidance on current topics of interest to the state boards of pharmacy through the use of single-issue task forces and work groups, and through various committees. Each group is appointed to address a specific charge and report its findings to the NABP Executive Committee. Task force, work group, and committee reports are published on the NABP website upon release.

Work Group on NABP's Multistate Inspection Blueprint Program

August 25-26, 2026

Charge:

1. Review the Multistate Inspection Blueprint Program Memorandum of Understanding (MOU) that states sign when joining the Multistate Inspection Blueprint Program.
2. Review the process by which NABP assists states to ensure compliance with the Multistate Inspection Blueprint Program.
3. Review the process by which NABP evaluates participating Blueprint states to determine compliance with the Multistate Inspection Blueprint Program, including ensuring that participating Blueprint states are fully inspecting for compliance with current United States Pharmacopeia (USP) sterile compounding standards.
4. Develop recommendations regarding the MOU and the processes mentioned above that will result in greater uniformity among states when it comes to required pharmacy compounding standards, specifically USP Chapter <797> Pharmaceutical Compounding – Sterile Preparations, and improved compliance with such standards, thus enhancing patient safety.

Chair

Caroline Juran (Virginia)

Members

Kristin Dimond (Montana)
Tim Fensky (Massachusetts)
Glen Gard (Illinois)
Debra Glass (Florida)
Alisha Henderson (Idaho)
Tyler Laetsch (South Dakota)
Brenda McCrady (Arkansas)
Mark Mikhael (Florida)
Taylor Rostova (Kentucky)
Joanna Robinson (Kansas)
Krystal Stefanyk (North Carolina)

Executive Committee Liaison

Dave Bowyer (West Virginia)

Task Force on Virtual Drug Manufacturer and Wholesale Distributor Facilities

September 14-15, 2026

Charge:

1. Review existing license requirements for manufacturer and wholesale distributor facilities that do not physically possess drugs.
2. Determine whether there is a need for additional requirements that are appropriate for a facility that does not physically possess drugs.
3. Determine whether there is a need for states to require licensure of designated representatives.
4. If necessary, recommend amendments to the *Model State Pharmacy Act and Model Rules of the National Association of Boards of Pharmacy (Model Act)* accordingly.

Chair

Mark Hardy (North Dakota)

Members

Tarek Al Nassif (Arizona)
Mike Burleson (Kentucky)
Tomson George (Illinois)
Traci Collier (South Carolina)
Reggie Dilliard (Tennessee)
Marjan Fardadfard (Oklahoma)
Michael Godek (Massachusetts)
Katrina Howard (Minnesota)
Donna Horn (Massachusetts)
Marveñe Martinez (Vermont)
J. Lindsey Tankersley (Arkansas)

Executive Committee Liaison

Shuler Spigener (South Carolina)

Task Force on Alternative Funding Programs

October 27-28, 2026

Charge:

1. Review the process by which prescription drug orders for US patients are directed to alternative funding programs for dispensing by unlicensed, foreign "pharmacies."
2. Review federal and state laws that address the dispensing of drugs to US patients by unlicensed, foreign "pharmacies."
3. Review board of pharmacy licensure and other requirements for these programs, if any.
4. Determine what actions, if any, the federal government or states can take to protect patients who are required by their prescription drug insurance plans to utilize alternative funding programs to fill their prescriptions.
5. If necessary, recommend amendments to the *Model Act* accordingly.

Chair

Chris Harlow (Kentucky)

Members

Sami Ahmed (Massachusetts)
Sabrina Beck (Nebraska)
Young Chang (Georgia)
Rick Fernandez (Texas)
Kevin Mitchell (Ohio)
Karen Ryle (Massachusetts)
Mark Sciaraffa (Massachusetts)
Kristen Snair (Arizona)
Darrell Switzer (Oklahoma)
Keith Vance (North Carolina)

Executive Committee Liaison

Matt Martineau (Wyoming)

Presidential Initiative Work Group – Approaches to Standard of Care Regulation

November 10-11, 2026

Charge:

1. Review standard of care regulations in those states that have them.
2. Review standard of care model language that was approved by the Committee on Law Enforcement/Legislation in 2026.
3. If necessary, recommend amendments to the *Model Act* accordingly.
4. Recommend additional actions NABP can take to expand resources for boards of pharmacy when exploring alternative regulatory pathways.

Chair

Alexandra Blasi (Kansas)

Members

Richard Breeden (Tennessee)
Robert Duncan (West Virginia)
Rob Geddes (Idaho)
Erik Maki (Iowa)
Ashley Schaber (Alaska)
Anne Schlepphorst (Iowa)
John Weitkamp (Wisconsin)

Executive Committee Liaison

Lorri Walmsley (Arizona)

Task Force on Long-Term Care Pharmacy Practice

January 13-14, 2027

Charge:

1. Review the February 24, 2026, letter to NABP from the National Community Pharmacists Association and the American Society of Consultant Pharmacists regarding contemporary long-term care (LTC) pharmacy practice and the needs of LTC patients.
2. Explore emerging pharmacy models beyond the traditional closed-door LTC pharmacy, such as a combination of retail and LTC pharmacy known as a "combo pharmacy," and the provision of LTC services within patients' homes.
3. Examine existing state regulations on LTC pharmacy and consider whether they adequately acknowledge the uniqueness of LTC practice.
4. Review the Model Rules for Institutional Pharmacy. As part of that review, reevaluate the following, as recommended by the Committee on Law Enforcement/Legislation in 2025:
    a. The definition of "chart order."
        i. Note that the definition contains allowances and requirements that might be best suited for inclusion in relevant rules.
        ii. Consider the term "quantity" versus "duration" of therapy, as requirements vary depending on the type of facility and whether the drug in question is categorized as non-controlled or controlled.
    b. The language in Section 2 of the Model Rules for Institutional Pharmacy pertaining to whether a pharmacist at a pharmacy located within an institutional facility should review every order prior to dispensing. The committee should consider Joint Commission guidelines during its review.
5. If necessary, recommend amendments to the *Model Act* accordingly.

Chair

John Kirtley (Arkansas)

Members

Darien-Lee Jennifer Castorina (New York)
Kim Croley (Kentucky)
Susan DelMonico (Rhode Island)
Laura Forbes (Virgin Islands)
Gray Fullwood (North Carolina)
Michelle Garvin (Iowa)
Bill Irvin (New Hampshire)
Jeenu Philip (Florida)
Maria Young (Michigan)

Executive Committee Liaison

Diane Halvorson (North Dakota)

Model Act Review Committee

January 25-26, 2027

Charge:

1. Conduct a thorough review of the *Model Act* to ensure the following are updated for relevance and accuracy:
    a. dates;
    b. footnotes;
    c. references to federal law and regulations and standard setting organizations, such as United States Pharmacopeial Convention and Accreditation Council for Pharmacy Education; and
    d. overall language to remove outdated provisions.
2. If necessary, make recommendations to the NABP Executive Committee regarding any section of the *Model Act* that should be considered for revision so that current pharmacy practice is accurately reflected.

Chair

Jeff Mesaros (Florida)

Members

Ruth Cassidy (New York)
Purvi Patel (New Hampshire)
Carrie Phillips (Vermont)
Daphanie Robinson (Maryland)
Dorinda Segovia (Florida)
Maria Serpa (California)
Stephanie Spark (Arizona)
Katie Thornell (Massachusetts)
Ellen Vick (North Carolina)

Executive Committee Liaison

Steve Schierholt (Ohio)

Committee on Law Enforcement/Legislation

March 2-3, 2027

Charge:

1. Develop model laws and regulations based on resolutions adopted by the members of the Association or reports of task forces or other committees of the Association, or as assigned by the Executive Committee.
2. Review and comment on existing legislation and rules governing the practice of pharmacy and the distribution of prescription medications.
3. Recommend to the Executive Committee model pharmacy practice or prescription drug distribution regulations that are needed to improve the protection of public health.

Chair

Jay Campbell (North Carolina)

Members

Beverly Black (South Carolina)
Paul Brand (Montana)
Ayanna Gardner (Illinois)
Marty Hendrick (Oklahoma)
Chris Hogan (Arizona)
John Rocchio (Massachusetts)
Lucy Shell (Tennessee)
Anne Sodergren (California)
Julie Spier (Texas)

Alternate

Kim Snyder (Indiana)

Executive Committee Liaison

Debbie Mack (Arkansas)

Committee on Constitution and Bylaws

April 6, 2027

Charge:

Defined by the Constitution and Bylaws.

Chair

Kayce Shealy (South Carolina)

Members

Dorothy Farfone (South Carolina)
Victoria Kroeger (Oregon)
Tiffany O'Hagan (Wisconsin)
Akash Patel (Maryland)

Alternate

Derek Webb (Virginia)

Executive Committee Liaison

Stacey Ranucci (Rhode Island)